JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

This research has direct clinical implications for AML, particularly in patients with KMT2A-rearranged and NPM1-mutated leukemia, who are currently being treated with menin inhibitors. By ...

Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the ...

JPMorgan raised the firm’s price target on Syndax (SNDX) to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant AML, which serves as a first step to providing ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant AML, which serves as a first step to providing ...

An expanded dataset for NPM1-mutant AML has shown an increase in response rates, while updated BEAT AML data remains strong with a high complete response rate (CRc) of 95%. These results have ...

The company’s KOMET-001 pivotal Phase 2 trial in relapsed/refractory NPM1-mutated AML has met its primary endpoint, with detailed results expected to be presented at a medical conference in the ...